Neurizon Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Neurizon Therapeutics possède un total de capitaux propres de A$10.2M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$11.1M et de A$896.6K.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$10.73m
Fonds propres	AU$10.23m
Total du passif	AU$896.61k
Total des actifs	AU$11.12m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NUZ ( A$11.1M ) dépassent ses passifs à court terme ( A$896.0K ).

Passif à long terme: Les actifs à court terme de NUZ ( A$11.1M ) dépassent ses passifs à long terme ( A$649.0 ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: NUZ est sans dette.

Réduire la dette: NUZ n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 4.4%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: NUZ dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: NUZ dispose d'une marge de trésorerie suffisante pour 1.3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 3 % chaque année.

Neurizon Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

PharmAust Limited, Annual General Meeting, Sep 30, 2024

PharmAust Limited has filed a Follow-on Equity Offering.

PharmAust Limited has completed a Follow-on Equity Offering in the amount of AUD 3.459 million.

PharmAust Limited has announced a Derivatives Offering in the amount of AUD 39.612456 million.

PharmAust Limited, Annual General Meeting, Nov 20, 2023

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

First half 2023 earnings released: EPS: AU$0 (vs AU$0.004 loss in 1H 2022)

PharmAust Limited Progresses to Elevated Doses in MND Patients

PharmAust Limited Completes First Cohort of Six Patients in Its Phase 1/2 Clinical Trial of Lead Drug Candidate Monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis

PharmAust Limited Announces MND Trial Completes Enrolment of First Patient Cohort

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

PharmAust Limited Recruits First Pet Dog with B Cell Lymphoma in US Canine Phase 2 Trial Assessing the Efficacy of Monepantel Treatment

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in FY 2021)

Pharmaust Updates on Canine Cancer Trials

PharmAust Limited Announces Resignation of Richard Mollard as Chief Scientific Officer

Pharmaust Limited Announces Arrival of Mpl Tablets in Melbourne for Motor Neuron Disease Clinical Trial

PharmAust Limited Expands Lymphoma Canine Trial to the USA

No independent directors

PharmAust Limited Announces Preliminary MPL Anti-Viral Leukaemia Preclinical WEHI Results

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

First half 2022 earnings: Revenues and EPS in line with analyst expectations

PharmAust Limited Provides Update on Manufacture of MPL & Tablets for Clinical Trials

Full year 2021 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2020)

Pharmaust Limited Achieves Phase IIB Dog Trial's Interim Clinical Endpoints

PharmAust Receives Ethics Approval for Phase I Trial of Monepantel in Motor Neurone Disease

PharmAust Limited Announces Phase IIb Canine Trial Identifies Therapeutic Window for MPL

PharmAust Ltd Provides an Update on Phase IIb Trial Testing the Effects of Monepantel Upon Pet Owners' Dogs with Treatment Naïve B Cell Lymphoma

PharmAust Limited Announces Monepantel COVID-19 Testing in the Netherlands

PharmAust and Leiden University Medical Centre Provide Update on Monepantel COVID-19 Testing

PharmAust and Olivia Newton-John Cancer Research Institute to Continue MPL Pre-clinical Investigations

PharmAust Ltd to Commence Phase IIb Dog Cancer Trial

PharmAust Limited Provides an Update on Analysis at the Olivia Newton-John Cancer Research Institute Investigating the Mechanism of Action of Monepantel Upon Cancer Cells

Pharmaust Ltd, Entered into A Service Agreement with Leiden University Medical Center (Lumc) in Netherlands for Lumc to Test

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines